Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract infections
and hospitalization in infants under 1 year of age and there is currently no market-approved …

MM cells express high levels of CD38, while CD38 is expressed at relatively low levels on
normal lymphoid and myeloid cells, and in some non-hematopoietic tissues. This expression …

Purpose: Previously our randomized phase III trial demonstrated that immunotherapy
including dinutuximab, a chimeric anti-GD2 mAb, GM-CSF, and IL2 improved survival for …

Natural killer (NK) cells play a major role in cancer immunotherapies that involve tumor-
antigen targeting by monoclonal antibodies (mAbs). NK cells express a variety of activating …

Mouse and human FcRs have been a major focus of attention not only of the scientific
community, through the cloning and characterization of novel receptors, and of the medical …

Enhancing immune responses with immune-modulatory monoclonal antibodies directed to
inhibitory immune receptors is a promising modality in cancer therapy. Clinical efficacy has …

Abstract Several anti–PD-1/PD-L1 monoclonal antibodies (mAb) are currently providing
evidence of clinical benefit in subsets of cancer patients. The mode of action of these mAbs …

The process of antibody-dependent cell-mediated cytotoxicity (ADCC) makes use of the
innate immune cells providing antitumor cytotoxicity activated by antibodies linked to target …

Tumor-associated macrophages (TAMs) promote key processes in tumor progression, like
angiogenesis, immunosuppression, invasion, and metastasis. Increasing studies have also …

During the past decades, anticancer immunotherapy has evolved from a promising
therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now …